A few weeks during a devistating manufactoring problem and eventual shut down of all production many men who were relying on Xofigo (radium-233 dichloride) were put into the untenable position of missing their scheduled doses. There was mass confusion about what to do in this circumstance. Men and their doctors didn't know if they should [...]
As of January 1, 2015 there will be some significant changes in the billing and reimbursement schedule for men receiving Bayer healthcare’s radium Ra223 dichloride (Xofigo). Xofigo is FDA approved for the treatment of men with castration-resistant metastatic prostate cancer (mCRPC) who have symptomatic bone metastases and no known visceral metastatic disease. These changes result [...]
Recently there have been a number of conversations in the prostate media around the topic of treating oligometastatic prostate cancer with a curative goal. Oligometastatic prostate cancer describes the disease state where primary treatment has failed as evidenced by an increasing PSA along with scanning evidence of a limited number of lymph nodes involved in [...]
On Dec 2, 2014 Astellas Pharma Europe Ltd announced that the European Commission (EC) has granted a variation that amends their marketing authorization for enzalutamide (Xtandi). Based on this amended authorization Xtandi is now approved in Europe for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic [...]
On December 7, 2014 the TV show 60 Minutes (CBS) aired a very interesting story (narrated by Dr. Sanjay Gupta) interview about an amazing sounding man, Dr. Patrick Soon-Shing. To describe him as a genius would be an unfair understatement. Dr. Soon-Shing is a billionaire who has already invested about $1 billion dollars of his [...]